Evidence map›Paper›PMID 42440851›Full record

ArticleMolecular therapy. Oncology2026

Next-generation LMP2A-targeting TCR-recombinant T cells with inducible IL-18 expression to treat EBV-associated malignancies.

Agnes Bonifacius, Philip Mausberg, Friederike Floegel, Anna Christina Dragon, Sabine Tischer-Zimmermann, Sven Stoll, Pegah Rahmati, Peter Spieler, María Fernanda Lammoglia Cobo, Anne Halenius and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Agnes BonifaciusInstitute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, 30625 Hannover, Germany.
Philip MausbergInstitute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, 30625 Hannover, Germany.
Friederike FloegelInstitute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, 30625 Hannover, Germany.
Anna Christina DragonInstitute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, 30625 Hannover, Germany.
Sabine Tischer-ZimmermannInstitute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, 30625 Hannover, Germany.
Sven StollInstitute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, 30625 Hannover, Germany.
Pegah RahmatiInstitute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, 30625 Hannover, Germany.
Peter SpielerChair for Cellular Immunotherapy, Department of Medicine II, University Hospital Würzburg, 97080 Würzburg, Germany.
María Fernanda Lammoglia CoboDepartment of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
Anne HaleniusInstitute of Virology, Medical Center University of Freiburg, 79106 Freiburg, Germany.
Hinrich AbkenDepartment Genetic Immunotherapy, Leibniz Institute for Immunotherapy, 93053 Regensburg, Germany.
Rainer BlasczykInstitute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, 30625 Hannover, Germany.
Thomas NerreterChair for Cellular Immunotherapy, Department of Medicine II, University Hospital Würzburg, 97080 Würzburg, Germany.
Michael HudecekChair for Cellular Immunotherapy, Department of Medicine II, University Hospital Würzburg, 97080 Würzburg, Germany.
Axel SchambachInstitute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany.
Leo HansmannDepartment of Internal Medicine III, Universitätsklinikum Regensburg, 93053 Regensburg, Germany.
Britta Maecker-KolhoffGerman Center for Infection Research (DZIF), Thematical Translation Unit-Immunocompromised Host (TTU-IICH), Partner Site Hannover-Braunschweig, Hannover, Germany.
Britta Eiz-VesperInstitute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, 30625 Hannover, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epstein-Barr virus (EBV) infects more than 90% of the population and establishes a lifelong persistence in memory B cells, passing through several latency stages (I-III). In immunocompromised patients, EBV infections and reactivations can lead to severe complications, such as post-transplant lymphoproliferative disorder (PTLD), a malignant B cell lymphoproliferation. The EBV latent membrane protein 2A (LMP2A) induces activation and proliferation of infected B cells and is expressed in latency stages II/III, that are associated with several EBV malignancies. Here, T cell receptor (TCR)-engineered T cells based on a TCR recognizing the clinically relevant HLA-A∗02:01-restricted LMP2A-derived peptide CLGGLLTMV (A∗02_LMP2A

Indexed as

4th generation CARadaptive immunityEpstein-Barr virusimmunotherapyLMP2Apost-transplant lymphoproliferative disorderT cellsT-cell therapyTCR engineering

Identifiers

PMID42440851
PMCPMC13334400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.